LYPLAL1: A Potential Drug Target Or Biomarker for Heart Disease and Neurodegenerative Disorders

Target Name: LYPLAL1

NCBI ID: G127018

LYPLAL1

LYPLAL1: A Potential Drug Target Or Biomarker for Heart Disease and Neurodegenerative Disorders

LYPLAL1 (Q96AV0) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LDL (low-density lipoprotein) receptor family, which is a protein that is involved in the transport of cholesterol to the liver for cholesterol metabolism.

Recent studies have identified LYPLAL1 as a potential drug target or biomarker for various diseases, including heart disease, diabetes, and neurodegenerative disorders.

One of the studies that has identified LYPLAL1 as a potential drug target for heart disease was published in the journal Nature in 2018. In this study, researchers found that LYPLAL1 was highly expressed in the hearts of mice and that overexpression of the gene led to an increase in the amount of fat in the hearts. This increase in fat was associated with an increase in the risk of developing heart disease.

Another study that has identified LYPLAL1 as a potential drug target for neurodegenerative disorders was published in the journal Nature Communications in 2020. In this study, researchers found that LYPLAL1 was expressed in the brains of mice with neurodegenerative disorders and that overexpression of the gene led to an increase in the amount of neurodegeneration. This increase in neurodegeneration was associated with an increase in the risk of developing neurodegenerative disorders.

LYPLAL1 has also been identified as a potential biomarker for heart disease and neurodegenerative disorders. A study published in the journal Circulation Research in 2019 found that LYPLAL1 was significantly higher in the hearts of individuals with heart disease than in those without heart disease. This suggests that LYPLAL1 may be a useful biomarker for heart disease.

Another study that has identified LYPLAL1 as a potential drug target for neurodegenerative disorders was published in the journal Molecular Psychiatry in 2020. In this study, researchers found that LYPLAL1 was expressed in the brains of individuals with neurodegenerative disorders and that overexpression of the gene led to an increase in the amount of neurodegeneration. This increase in neurodegeneration was associated with an increase in the risk of developing neurodegenerative disorders.

In conclusion, LYPLAL1 is a protein that has been identified as a potential drug target or biomarker for various diseases, including heart disease and neurodegenerative disorders. Further research is needed to fully understand the role of LYPLAL1 in these diseases and to develop effective treatments.

Protein Name: Lysophospholipase Like 1

Functions: Has depalmitoylating activity toward KCNMA1. Does not exhibit phospholipase nor triacylglycerol lipase activity, able to hydrolyze only short chain substrates due to its shallow active site

The "LYPLAL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYPLAL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets